Kurser indlæses...
Prognose
Analytikernes gennemsnitlige kursmål er 224,26 € (+2,75 %). Medianen er 208,92 € (-4,27 %).
| Køb |
Â
14 |
| Behold |
Â
17 |
| Sælg |
Â
5 |
Diskussioner i communityet
Der er endnu ingen diskussion om dette aktiv.
Start diskussionNyheder Til nyhedsfeedet
ResMed expands sleep portfolio with Noctrix acquisition as OSA demand supports outlook
ResMed completed the acquisition of Noctrix to add Nidra TOMAC therapy for restless legs syndrome and integrate wearable RLS treatment into its connected health ecosystem. KeyBanc kept an Overweight rating but trimmed its price target to $266, citing continued momentum in the OSA and CPAP markets driven by GLP-1 adoption and consumer wearables. The moves aim to strengthen ResMed’s position in home-based sleep and respiratory care amid growing patient demand. » Mere på finance.yahoo.com
ResMed Inc. undervalued as GLP-1 fears seen as overblown
A bullish thesis argues ResMed Inc. is mispriced due to overstated risks from GLP-1 weight‑loss drugs, while structural demand for sleep apnea and recurring consumables revenue remain intact. The company’s AirView connected care platform and recurring replacement cycles support high gross margins and strong switching costs, with about 22 million connected devices and an estimated 936 million potential patients globally. ResMed generates roughly $2.2 billion in annual free cash flow and currently trades below its historical quality multiple, presenting a potential long-term re‑rating opportunity. » Mere på finance.yahoo.com
ResMed: margins rise sharply thanks to rapidly growing digital health ecosystem
ResMed reported Q3 FY26 revenue of $1.43bn (+8% constant currency) and adjusted EPS of $2.86 (+21%), with the stock holding steady in after-hours trading. Adjusted gross margin rose to 62.8% (+290 basis points) and operating margin to 36.7%, driven by platform standardization, scale effects and efficiency improvements. The connected ecosystem continues to expand: 36 million registered patients on AirView, 34 million cloud-capable devices and 26 billion nights of respiratory data; ResMed also announced the acquisition of Noctrix Health for $340m. The company reaffirmed its margin guidance for FY26 and targets long-term revenue growth in the high single digits, with earnings growth outpacing revenue growth. » Mere på de.investing.com
ResMed Q3 2026: earnings per share beat forecast, revenue slightly below expectations
ResMed reported Q3 FY2026 EPS of $2.86 versus an expected $2.81, thereby topping estimates, while revenue of $1.43 billion narrowly missed the $1.42 billion forecast. Revenue grew 11%, supported by a 12% rise in masks and accessories; gross margin increased to 62.8% and operating margin to 36.7%. Management emphasized continued margin improvements through cost efficiency and mix optimization; the stock traded flat in after-hours near $212. » Mere på de.investing.com
ResMed hits 52-week low at $218.27 after prolonged decline
ResMed stock is trading at $218.20 and has reached a new 52-week low, 26% below the year high and down 7.6% over 12 months (16% over six months). For the second fiscal quarter ResMed reported EPS of $2.81 (expectation $2.73) and revenue of $1.4 billion, in line with expectations. Analysts were mostly positive: RBC and KeyBanc raised price targets, Needham and Stifel confirmed ratings, and InvestingPro points to management’s aggressive share buybacks as a signal of confidence. » Mere på de.investing.com
Historisk udbytte Udbytte
Alle nøgletal for udbytte Alle nøgletalVirksomhedstal
| (EUR) | september 2026 | YoY |
|---|---|---|
| Omsætning | 1,25 mia. | 9,75 % |
| Bruttofortjeneste | 768,58Â mio. | 9,88Â % |
| Nettoresultat | 369,4Â mio. | 24,38Â % |
| EBITDA | 517,09Â mio. | 18,23Â % |
Fundamentale data
| Nøgletal | Værdi |
|---|---|
Markedsværdi | 30,6 mia. € |
Antal aktier | 140,66Â mio. |
Højeste/laveste i 52 uger | 252,22 € - 163,74 € |
Udbytteafkast | 0,98Â % |
Udbytte TTM | 2,13 € |
Beta | 0,76 |
P/E (PE Ratio) | 21,80 |
PEG (PEG Ratio) | 1,81 |
K/I (PB Ratio) | 5,76 |
P/S (PS Ratio) | 5,88 |
Virksomhedsprofil
ResMed Inc. udvikler, fremstiller, distribuerer og markedsfører medicinsk udstyr og skybaserede softwareapplikationer til sundhedsmarkedet. Virksomheden opererer i to segmenter, Sleep and Respiratory Care samt Software as a Service. Den tilbyder forskellige produkter og løsninger til en række luftvejslidelser, herunder teknologier til anvendelse i medicinske og forbrugerprodukter, ventilationsudstyr, diagnostiske produkter, maskesystemer til brug på hospitaler og i hjemmet, hovedbøjler og andet tilbehør, tandudstyr og skybaserede softwareinformatikløsninger til styring af patientresultater samt leverer kunde- og forretningsprocesser. Virksomheden leverer også AirView, et skybaseret system, der muliggør fjernmonitorering og ændring af patienters udstyrsindstillinger; myAir, en personligt tilpasset terapistyringsapplikation til patienter med søvnapnø, som giver støtte, undervisning og fejlfindingsværktøjer for øget patientengagement og forbedret compliance; U-Sleep, en complianceovervågningsløsning, der gør det muligt for leverandører af medicinsk hjælpeudstyr til hjemmet (HME) at effektivisere deres søvnprogrammer; samt forbindelsesmoduler og propeller-løsninger. Derudover tilbyder den out-of-hospital softwareløsninger, såsom Brightree forretningsstyringssoftware og serviceløsninger til udbydere af HME-, apotek-, hjemmeinfusions-, ortotik- og protesetjenester; MatrixCare care management og tilhørende supplerende løsninger til senior living, plejehjem, life plan communities, hjemmesygepleje, hjemmepleje og hospice-bureauer samt tilhørende accountable care organizations; og HEALTHCAREfirst, som tilbyder elektroniske patientjournaler, software, fakturerings- og kodningstjenester samt analyse for hjemmesygepleje- og hospice-bureauer. Virksomheden markedsfører sine produkter primært til søvnklinikker, forhandlere af hjemmesundhedsudstyr og hospitaler gennem et netværk af distributører og en direkte salgsstyrke i cirka 140 lande. ResMed Inc. blev grundlagt i 1989 og har hovedkontor i San Diego, Californien.
| Navn | ResMed |
| CEO | Michael J. Farrell |
| Hjemsted | San Diego,
ca USA |
| Websted | |
| Sektor | Sundhed |
| Branche | Sundhedsteknologi |
| Børsnotering | 02.06.1995 |
| Medarbejdere | 11.370 |
Tickersymboler
| Børs | Symbol |
|---|---|
NYSE | RMD |
London Stock Exchange | 0KW4.L |
Frankfurt | RME.F |
DĂĽsseldorf | RME.DU |
London | 0KW4.L |
SIX | RME.SW |
MĂĽnchen | RME.MU |
Wien | RMD.VI |